Header Logo

Connection

MAKSIM MAMONKIN to Humans

Back to Details
This is a "connection" page, showing publications MAKSIM MAMONKIN has written about Humans.
MAKSIM MAMONKIN
Connection Strength
0.397
Humans
  1. Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell Rep Med. 2024 Jul 16; 5(7):101628.
    View in: PubMed
    Score: 0.025
  2. SOHO State of the Art Updates and Next Questions | CAR T Cells in T Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Clin Lymphoma Myeloma Leuk. 2025 Feb; 25(2):77-88.
    View in: PubMed
    Score: 0.025
  3. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 03 28; 143(13):1231-1241.
    View in: PubMed
    Score: 0.025
  4. Engineering T cells to suppress acute GVHD and?leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2023 03 09; 141(10):1194-1208.
    View in: PubMed
    Score: 0.023
  5. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T?cells for T?cell malignancies. Mol Ther. 2023 01 04; 31(1):24-34.
    View in: PubMed
    Score: 0.022
  6. CD7 CAR: sword and shield. Blood. 2022 07 28; 140(4):293-294.
    View in: PubMed
    Score: 0.022
  7. Off-the-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There? Cancer J. 2021 Mar-Apr 01; 27(2):176-181.
    View in: PubMed
    Score: 0.020
  8. Detonating T-ALL. Blood. 2020 09 10; 136(11):1218-1219.
    View in: PubMed
    Score: 0.019
  9. Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63.
    View in: PubMed
    Score: 0.019
  10. CRISPR-Edited Immune Effectors: The End of the Beginning. Mol Ther. 2020 04 08; 28(4):995-996.
    View in: PubMed
    Score: 0.019
  11. Generation of Chimeric Antigen Receptor T Cells Using Gammaretroviral Vectors. Methods Mol Biol. 2020; 2086:119-130.
    View in: PubMed
    Score: 0.018
  12. Analysis of CAR-Mediated Tonic Signaling. Methods Mol Biol. 2020; 2086:223-236.
    View in: PubMed
    Score: 0.018
  13. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017 07 20; 130(3):285-296.
    View in: PubMed
    Score: 0.015
  14. Exhausting alloreactivity of donor-derived CAR T cells. Nat Med. 2017 02 07; 23(2):147-148.
    View in: PubMed
    Score: 0.015
  15. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015 Aug 20; 126(8):983-92.
    View in: PubMed
    Score: 0.013
  16. Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy. Stem Cells Transl Med. 2025 May 31; 14(6).
    View in: PubMed
    Score: 0.007
  17. Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells. Sci Adv. 2025 Jan 10; 11(2):eadq8114.
    View in: PubMed
    Score: 0.007
  18. Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia. Blood. 2024 04 25; 143(17):1726-1737.
    View in: PubMed
    Score: 0.006
  19. Human platelet lysate enhances in vivo activity of CAR-Vd2 T cells by reducing cellular senescence and apoptosis. Cytotherapy. 2024 Aug; 26(8):858-868.
    View in: PubMed
    Score: 0.006
  20. Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2023 03; 29(3):165.e1-165.e7.
    View in: PubMed
    Score: 0.006
  21. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies. Blood. 2022 12 22; 140(25):2684-2696.
    View in: PubMed
    Score: 0.006
  22. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
    View in: PubMed
    Score: 0.005
  23. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2022 01; 160:112-133.
    View in: PubMed
    Score: 0.005
  24. Taking T-Cell Oncotherapy Off-the-Shelf. Trends Immunol. 2021 03; 42(3):261-272.
    View in: PubMed
    Score: 0.005
  25. Modulating TNFa activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer. 2020 09; 8(2).
    View in: PubMed
    Score: 0.005
  26. Adult and Cord Blood-Derived High-Affinity gB-CAR-T Cells Effectively React Against Human Cytomegalovirus Infections. Hum Gene Ther. 2020 04; 31(7-8):423-439.
    View in: PubMed
    Score: 0.005
  27. Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. Cancer Immunol Res. 2020 03; 8(3):309-320.
    View in: PubMed
    Score: 0.005
  28. Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. Cancer J. 2019 May/Jun; 25(3):199-207.
    View in: PubMed
    Score: 0.004
  29. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Mol Ther. 2019 01 02; 27(1):272-280.
    View in: PubMed
    Score: 0.004
  30. Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep. 2017 Oct 03; 21(1):17-26.
    View in: PubMed
    Score: 0.004
  31. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
    View in: PubMed
    Score: 0.004
  32. Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells. J Immunol. 2017 07 01; 199(1):348-362.
    View in: PubMed
    Score: 0.004
  33. [CAR T-cell therapy: Balance of efficacy and safety]. Mol Biol (Mosk). 2017 Mar-Apr; 51(2):274-287.
    View in: PubMed
    Score: 0.004
  34. Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52.
    View in: PubMed
    Score: 0.004
  35. FCRL6 receptor: expression and associated proteins. Immunol Lett. 2011 Jan 30; 134(2):174-82.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.